NASDAQ: SCYXScynexis Inc Stock
$1.47-0.03 (-2%)
Updated Apr 25, 2024
SCYX Price
$1.47
Fair Value Price
N/A
Market Cap
$55.50M
52 Week Low
$1.35
52 Week High
$3.87
P/E
1.05x
P/B
0.76x
P/S
0.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$140.14M
Earnings
$67.04M
Gross Margin
88.9%
Operating Margin
50.17%
Profit Margin
47.8%
Debt to Equity
0.76
Operating Cash Flow
$60M
Beta
0.99
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SCYX Overview
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SCYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCYX is good value based on its earnings relative to its share price (1.05x), compared to the US market average (40.97x)
P/E vs Market Valuation
SCYX is good value based on its earnings relative to its share price (1.05x), compared to the US Drug Manufacturers - Specialty & Generic industry average (33.56x)
P/E vs Industry Valuation
SCYX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more SCYX due diligence checks available for Premium users.
Be the first to know about important SCYX news, forecast changes, insider trades & much more!
SCYX News
Valuation
SCYX fair value
Fair Value of SCYX stock based on Discounted Cash Flow (DCF)
Price
$1.47
Fair Value
-$0.15
Undervalued by
1,081.39%
SCYX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
1.05x
Industry
33.56x
Market
40.97x
SCYX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SCYX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SCYX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.76x
Industry
2.07x
SCYX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SCYX's financial health
Profit margin
Revenue
$5.8M
Net Income
-$19.6M
Profit Margin
-337.9%
SCYX's Earnings (EBIT) of $70.31M... subscribe to Premium to read more.
Interest Coverage Financials
SCYX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$128.4M
Liabilities
$55.5M
Debt to equity
0.76
SCYX's short-term assets ($102.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCYX's short-term assets ($102.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCYX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SCYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.7M
Investing
-$2.2M
Financing
-$135.0k
SCYX's operating cash flow ($60.16M)... subscribe to Premium to read more.
Debt Coverage Financials
SCYX vs Pharmaceutical Stocks
Scynexis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.